Display options
Share it on

Int J Angiol. 2012 Dec;21(4):187-94. doi: 10.1055/s-0032-1330232.

A review of the role of anticoagulation in the treatment of peripheral arterial disease.

The International journal of angiology : official publication of the International College of Angiology, Inc

Thomas F Whayne

Affiliations

  1. Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky.

PMID: 24293975 PMCID: PMC3578611 DOI: 10.1055/s-0032-1330232

Abstract

Peripheral arterial disease (PAD) is a major medical/surgical problem associated with high risk for coronary heart disease (CHD). Anticoagulation plays a significant role in the management of the PAD patient. However, evidence-based medicine supports only select anticoagulants, mainly antiplatelet agents. The available anticoagulant classes, their individual medications, and the mechanisms of action are described. Dextran 40, platelet glycoprotein (GP) IIb/IIIa receptor antagonists, direct thrombin (factor IIa, FIIa) inhibitors, and factor Xa (FXa) inhibitors do not, at this juncture, appear to have a significant role to play in the PAD patient. Aspirin has been used in PAD patients for a few decades, as has warfarin, but the role of warfarin is very limited. An attempt has been made to place each medication and its function in context all the way to the present with oral direct thrombin (FIIa) and FXa inhibitors described. These inhibitors may ultimately play an, as yet, undefined role in PAD. Specific use of anticoagulants in PAD patients is described and aspirin still stands out as a fundamental therapy. The thienopyridines, especially clopidogrel, have their established place and there is some evidence for benefit from the use of clopidogrel in dual therapy with aspirin. Dipyridamole, especially with aspirin as dual therapy, and cilostazol also have their evidence-based niches. The main role played by warfarin is for the patient with a vein graft in the arterial circulation. Heparin retains significant procedural importance. For now, Class I, Level of Evidence A center around aspirin for the PAD patient with clopidogrel, an alternative agent.

Keywords: anticoagulation; aspirin; cardiovascular disease; coronary artery; peripheral arterial disease; risk factors; thienopyridines

References

  1. Br J Surg. 2005 Feb;92(2):159-65 - PubMed
  2. J Clin Invest. 1975 Sep;56(3):624-32 - PubMed
  3. Cardiology. 2005;103(3):158-60 - PubMed
  4. Lancet. 1985 Feb 23;1(8426):415-9 - PubMed
  5. Lancet. 1992 Jul 18;340(8812):143-5 - PubMed
  6. Chest. 2008 Jun;133(6 Suppl):199S-233S - PubMed
  7. J Vasc Surg. 1998 Jul;28(1):23-6; discussion 26-7 - PubMed
  8. Cardiol Rev. 2011 Mar-Apr;19(2):95-100 - PubMed
  9. J Clin Invest. 1983 Nov;72(5):1521-5 - PubMed
  10. N Engl J Med. 2011 Sep 8;365(10):883-91 - PubMed
  11. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  12. Chest. 2005 Feb;127(2 Suppl):53S-59S - PubMed
  13. J Vasc Surg. 2004 May;39(5):977-84 - PubMed
  14. N Engl J Med. 2006 Apr 20;354(16):1706-17 - PubMed
  15. Chest. 1992 Oct;102(4 Suppl):337S-351S - PubMed
  16. J Vasc Surg. 1998 Sep;28(3):446-57 - PubMed
  17. Curr Pharm Des. 2003;9(28):2289-302 - PubMed
  18. J Clin Invest. 1968 Sep;47(9):2169-80 - PubMed
  19. Int J Cardiol. 2011 Aug 4;150(3):325-31 - PubMed
  20. Chest. 2012 Feb;141(2 Suppl):e669S-e690S - PubMed
  21. J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2 - PubMed
  22. J Neurol Sci. 1996 Nov;143(1-2):1-13 - PubMed
  23. J Vasc Surg. 1998 Feb;27(2):267-74; discussion 274-5 - PubMed
  24. Catheter Cardiovasc Interv. 2012 Mar 1;79(4):501-31 - PubMed
  25. N Engl J Med. 2009 Sep 3;361(10):940-2 - PubMed
  26. Circulation. 2005 Feb 8;111(5):633-42 - PubMed
  27. Lancet. 2000 Jan 29;355(9201):346-51 - PubMed
  28. Blood Coagul Fibrinolysis. 2011 Oct;22(7):565-70 - PubMed
  29. Med Sci Monit. 2009 Dec;15(12):MS24-30 - PubMed
  30. J Am Coll Cardiol. 2011 Mar 15;57(11):1251-63 - PubMed
  31. J Vasc Surg. 2005 Aug;42(2):252-8 - PubMed
  32. Cochrane Database Syst Rev. 2011 Nov 09;(11):CD001272 - PubMed
  33. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD002071 - PubMed
  34. Eur J Vasc Endovasc Surg. 1996 Jul;12(1):86-90 - PubMed
  35. Am Heart J. 1990 Dec;120(6 Pt 1):1414-8 - PubMed
  36. Clin Appl Thromb Hemost. 2004 Jan;10(1):9-18 - PubMed
  37. J Vasc Interv Radiol. 2005 Feb;16(2 Pt 1):165-71 - PubMed
  38. Br J Pharmacol. 2006 Jan;147 Suppl 1:S241-51 - PubMed
  39. Catheter Cardiovasc Interv. 2009 Jul 1;74 Suppl 1:S7-S11 - PubMed
  40. N Engl J Med. 2011 Sep 15;365(11):981-92 - PubMed
  41. J Vasc Surg. 1997 Sep;26(3):517-38 - PubMed
  42. Br J Haematol. 2008 Jun;141(6):757-63 - PubMed
  43. N Engl J Med. 2007 Nov 15;357(20):2001-15 - PubMed
  44. Platelets. 2004 Jun;15(4):215-22 - PubMed
  45. Drug Metab Dispos. 2010 Jan;38(1):92-9 - PubMed
  46. Circulation. 2009 Dec 22;120(25):2577-85 - PubMed
  47. Blood Transfus. 2009 Jan;7(1):18-23 - PubMed
  48. Am J Surg. 1990 Jun;159(6):556-60 - PubMed
  49. BMJ. 1994 Jan 15;308(6922):159-68 - PubMed
  50. Circulation. 2010 Jun 15;121(23):2584-91 - PubMed
  51. Thromb Res. 1988 Dec 1;52(5):353-9 - PubMed
  52. J Am Coll Cardiol. 2011 Feb 8;57(6):672-84 - PubMed
  53. JAMA. 2001 Sep 19;286(11):1317-24 - PubMed
  54. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD000536 - PubMed
  55. J Vasc Surg. 2002 Mar;35(3):413-21 - PubMed
  56. Lancet Neurol. 2010 Oct;9(10):959-68 - PubMed
  57. Nature. 2001 Jan 11;409(6817):202-7 - PubMed

Publication Types